Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)

NCT02246439 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT02246439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02246439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2014
Completion date
February 16, 2017
Enrollment
330 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

gastritis, gastroenteritis